Pioglitazone tablet is not for people with type 1 diabetes. Pioglitazone tablet is not for people with diabetic ketoacidosis (increased ketones in your blood or urine). Who should not take pioglitazone tablets? See What is the most important information I should know about pioglitazone tablets? Do not take pioglitazone tablets if you:
Pioglitazone Brand name: Actos. Find out how pioglitazone treats type 2 diabetes and how to take it. About pioglitazone Who can and cannot take it
The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.
Who should not take pioglitazone and glimepiride tablets? See What is the most important information I should know about pioglitazone and glimepiride tablets?
The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.
Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs. Pioglitazone should not be used in patients with heart failure or a history of heart failure. Pioglitazone: risk of bladder cancer (July 2024)
Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs. Pioglitazone should not be used in patients with heart failure or a history of heart failure. Pioglitazone: risk of bladder cancer (July 2024)
The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.
What should I discuss with my healthcare provider before taking pioglitazone? You should not use this medicine if you are allergic to pioglitazone, or if you
Comments